It looks to me that you are either a psycho or an angry ex-employee who got fired. The $33M is a manufacturing contract obligation for future drug manufacturing. A savvy CFO should be able to negotiate a new term that is contingent upon the reintroduction of Omontys. The $11M debt obligation under existing credit facility is not due imminently and can be refinance with the bank (especially in today's credit environment). The $8 to $10M severence is an one time hit.
Affymax has turned over the investigation to Takeda, so Takeda will be incurring the cost of investigation and the cost of product reintroduction!!
So, the $67M should last a long long time, if Affymax management conserves.
You sure like bringing up stuff from 8K with your own twist. Here is an excerpt from Feb 13, 2013 8K that you probably missed and it is from Franklin W. Maddux, MD, FACP, Chief Medical Officer Executive VP For Clinical and Scientific Affairs from Fresenius Medical Care North America:
"We have accumulated experience in more than 56,600 administrations in over 18,000 unique patients. Two months into the FMCNA pilot program, the FDA released revised product information that added language similar to the prescribing information for EPOGEN® concerning the risk for allergic reactions, which we communicated to you in November 2012. To date, we have seen infrequent allergic reactions in our patient population receiving their first dose of OMONTYS®. Most of these reactions have been mild, but a small number have been serious. The rate of allergic reactions has been on the order of 1:1000 patients receiving a first dose of OMONTYS®. The vast majority of patients who are receiving the medication on an ongoing monthly basis are tolerating it well."
We have seen INFREQUENT ALLERGIC REACTIONS!!!!! This is from the Chief Medical Officer from Fresenius!!!!! And not some Godwinpeak talking head on Yahoo message boards!